MEDICATION TRIALS: Treatment Naïve – No PAST USE OF ANTIRETROVIRAL THERAPY
|
ViiV HealthCare/Pfizer - A4001095: A multicenter, randomized, double-blind, comparative trial of Maraviroc+Darunavir /Ritonavir versus Emtricitabine/Tenofovir + Darunavir /Ritonavir for the treatment of antiretroviral-naïve HIV infected patients with CCR5 Tropic HIV-1
NCT01345630(?)
|
PI: Steven Santiago, M.D
Contacts for further information:
Leandro Pisani
305/576-1234 ext 276
lpisani@careresource.org
or
Milagros Rodriguez
305/576-1234 ext 244
mrodriguez@careresource.org
|
Recruitment Begins 9/15/2011
|
MEDICATION TRIALS: Treatment Naïve – No PAST USE OF ANTIRETROVIRAL THERAPY
ELIGIBILITY :
Men and women ≥ 18 yrs of age who have never taken antiretroviral drugs and have a viral load > 1000 copies/ml and
CD4 > 100 cells/mm3
|
|
MEDICATION TRIALS: Treatment Naïve – No PAST USE OF ANTIRETROVIRAL THERAPY
|
Tobira Therapeutics -652-2-202: A phase 2b,
multicenter, double blind comparative study to evaluate the efficacy, safety and tolerability of Cenicriviroc in HIV‐1 infected, antiretroviral treatment‐naïve patients with only CCR5‐tropic virus. Participants will receive either once‐daily 100 mg or 200 mg doses of Cenicriviroc in combination with Truvada or once‐daily Sustiva plus Truvada.
|
PI: Steven Santiago, M.D
Contacts for further information:
Leandro Pisani
305/576-1234 ext 276
lpisani@careresource.org
or
Milagros Rodriguez
305/576-1234 ext 244
mrodriguez@careresource.org
|
Recruitment Begins 8/20/2011
|
MEDICATION TRIALS: Treatment Naïve – No PAST USE OF ANTIRETROVIRAL THERAPY
Eligibility:
Men and women >
18 years of age with CCR5-tropic virus by GT and Trofile-ES who have never taken antiretroviral drugs; viral load > 5,000 copies/ml and CD4 > 250 cells/mm3
|
|
MEDICATION TRIALS: Treatment Naïve – No PAST USE OF ANTIRETROVIRAL THERAPY
|
Viiv HealthCare/ Pfizer - A4001098: A multi-center, randomized, blinded, placebo-controlled study to evaluate the safety of Maraviroc in combination with other antiretroviral agents in HIV-1-infected subjects co-infected with Hepatitis C and/or Hepatitis B virus.
|
PI: Luis Saenz D.O
Contacts for further information:
Leandro Pisani
305/576-1234 ext 276
lpisani@careresource.org
or
Milagros Rodriguez
305/576-1234 ext 244
mrodriguez@careresource.org
|
Enrollment Open
|
MEDICATION TRIALS: Treatment Naïve – No PAST USE OF ANTIRETROVIRAL THERAPY
Eligibility:
≥ 18 yrs of age co-infected with Hepatitis C or B and not receiving treatment. for Hepatitis B or C. Undectectable viral load for at least 3 months. No prior treatment with Maraviroc or another CCR5
|
|
MEDICATION TRIALS: Treatment Naïve – No PAST USE OF ANTIRETROVIRAL THERAPY
|
EPZ113734 - A Prospective, Randomized, Multicenter, Open-Label Study to Compare the Efficacy and Safety of Simplifying from a Regimen of Atazanavir + Ritonavir + Tenofovir/Emtricitabine to Atazanavir + Abacavir/Lamivudine Without Ritonavir for 48
|
PI: Steven Santiago, M.D.
Luis Saenz D.O.
Contacts for further information:
Milagros Rodriguez
305/576-1234 ext 244
mrodriguez@careresource.org
|
|
MEDICATION TRIALS: Treatment Naïve – No PAST USE OF ANTIRETROVIRAL THERAPY
|
|
MEDICATION TRIALS: Treatment experienced (history of Current or Past Use of Antiretroviral Therapy)
|
GlaxoSmithKline -EPZ113734: A prospective, randomized, multicenter, open-label study to compare the efficacy and safety of simplifying from a regimen of Atazanavir + Ritonavir/Tenofovir/ Emtricitabine to Atazanavir + Abacavir/ Lamivudine without Ritonovir for 48 weeks in virologically suppressed, HIV-infected HLA-B 5701 negative subjects
|
PI: Steven Santiago, M.D.
Contacts for further information:
Leandro Pisani
305/576-1234 ext 276
lpisani@careresource.org
or
Milagros Rodriguez
305/576-1234 ext 244
mrodriguez@careresource.org
|
Enrollment Open
|
MEDICATION TRIALS: Treatment experienced (history of Current or Past Use of Antiretroviral Therapy)
Eligibility:
18 yrs of age who have been undetectable for more than 3 months and receiving a regimen of ATV/RTV (300mg/100 mg) +TDF/FTC (300mg/200 mg) as initial or first and only switch regimen for at least 6 months.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Yüklə 1.25 Mb.